ESTRELLA IMMUNOPHARMA, INC. Financing Receivable Transfer To Held For Sale Valuation Allowance Expense
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Financing Receivable Transfer To Held For Sale Valuation Allowance Expense of $23.52 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Notes
us-gaap:FinancingReceivableTransferToHeldForSaleValuationAllowanceExpense · last filed 2023-08-01
- ESTRELLA IMMUNOPHARMA, INC. financing receivable transfer to held for sale valuation allowance expense for the quarter ending 2023-06-30 was $23.52K, a 68.85% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. financing receivable transfer to held for sale valuation allowance expense for the quarter ending 2022-06-30 was $75.51K.
| Period end | Financing Receivable Transfer To Held For Sale Valuation Allowance Expense 3 month | Financing Receivable Transfer To Held For Sale Valuation Allowance Expense 6 month |
|---|---|---|
| 2023-06-30 | $23.52K 10-Q · filed 2023-08-01 | $52.20K 10-Q · filed 2023-08-01 |
| 2022-06-30 | $75.51K 10-Q · filed 2023-08-01 | $105.18K 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |